Johnson & Johnson (NYSE:JNJ) EVP Elizabeth Forminard Sells 15,918 Shares

Johnson & Johnson (NYSE:JNJ) EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Johnson & Johnson Trading Up 0.8%

Shares of Johnson & Johnson stock opened at $259.03 on Friday. Johnson & Johnson has a 12-month low of $170.39 and a 12-month high of $274.90. The firm’s 50 day simple moving average is $248.47 and its two-hundred day simple moving average is $239.73. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $624.23 billion, a price-to-earnings ratio of 30.01, a PEG ratio of 2.45 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm’s revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Dividend appeal remains a key support. Recent coverage highlights JNJ as a blue-chip income stock with a long record of dividend growth and defensive fundamentals, which may attract investors seeking stability amid elevated interest rates. Why is Johnson & Johnson drawing dividend attention today? Top dividend stocks to buy and hold
• Positive Sentiment: Reported talc settlement removes a major legal overhang. JNJ agreed to a reported $5.5 billion settlement covering tens of thousands of talc lawsuits. While costly, resolving the claims could improve legal and financial visibility and reduce uncertainty surrounding the company. Johnson & Johnson reaches $5.5 billion talc settlement
• Positive Sentiment: Citi issued a Buy rating, adding to the favorable analyst backdrop. JNJ’s latest reported quarter also exceeded expectations, with revenue rising 6.6% year over year and earnings surpassing consensus estimates. Johnson & Johnson gets a Buy from Citi
• Neutral Sentiment: Coverage says JNJ has remained steady during a division transition. The company is also investing more than $1 billion to expand U.S. contact-lens production, a potential long-term growth initiative, although near-term returns remain uncertain. Why Johnson & Johnson is steady amid a division transition
• Negative Sentiment: The talc agreement represents a substantial cash and earnings burden, and investors may continue evaluating whether the settlement fully resolves future claims and related costs.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. JPMorgan Chase & Co. increased their target price on Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research note on Monday. Scotiabank reiterated an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, Wall Street Zen lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $268.22.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors have recently added to or reduced their stakes in the stock. Harborfront Financial Group LLC acquired a new position in Johnson & Johnson during the second quarter worth $130,000. Pension & Wealth Management Advisors Inc. grew its holdings in Johnson & Johnson by 14.0% in the 2nd quarter. Pension & Wealth Management Advisors Inc. now owns 2,069 shares of the company’s stock valued at $526,000 after buying an additional 254 shares in the last quarter. Citizens Financial Group Inc. RI increased its stake in shares of Johnson & Johnson by 1.9% in the 2nd quarter. Citizens Financial Group Inc. RI now owns 210,648 shares of the company’s stock worth $53,498,000 after acquiring an additional 3,848 shares during the last quarter. Aegis Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 4.3% during the 2nd quarter. Aegis Wealth Management LLC now owns 2,583 shares of the company’s stock worth $656,000 after acquiring an additional 106 shares during the period. Finally, UNIVEST FINANCIAL Corp raised its holdings in shares of Johnson & Johnson by 1.4% during the 2nd quarter. UNIVEST FINANCIAL Corp now owns 69,498 shares of the company’s stock worth $17,650,000 after acquiring an additional 985 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.